Developer docs
API playgroundTry for free, no card

Search company profiles

Primmune Therapeutics

Full company profile

uuid0002b7a

Namestring
Primmune Therapeutics
Legal namestring
Primmune Therapeutics, Inc.
Websiteurl
primmunerx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Primmune Therapeutics is a clinical-stage biotechnology company developing PRTX007, a novel, orally administered, systemically active small-molecule agonist of toll-like receptor 7 (TLR7). PRTX007 is designed as a prodrug that converts to active metabolite PRX034 and selectively activates plasmacytoid dendritic cells (pDCs) to generate Type I and Type III interferon-associated innate immune programs while deliberately minimizing engagement of NF-κB-driven pro-inflammatory pathways that have historically limited systemic TLR7/8 agonists. The company has coined the term "TherAjuvant" to describe PRTX007's combined therapeutic and adjuvant mechanism, intended to coordinate innate and adaptive immunity while preserving lymph node function.

The company's clinical strategy spans oncology (solid tumors, neoadjuvant melanoma in combination with anti-PD-1 therapy) and viral diseases (RSV, COVID-19, HPV-driven high-grade squamous intraepithelial lesions, Lassa Fever, and hepatitis B/D). As of early 2026, PRTX007 had been administered to 119 healthy volunteers across two Phase 1 studies (PRTX007-001 and PRTX007-002) with a favorable safety profile and no serious adverse events, and the company had initiated a Phase 2 neoadjuvant study in Stage III resectable melanoma in Australia under Novotech. The company is led by co-founders Charlie McDermott (President & CEO), James Appleman (SVP R&D/CSO), Paulo Rangel (CBO), and Stephen Webber (VP Medicinal Chemistry), with a recent CMO appointment of Andrew Sharabi, MD, PhD.

Primmune is pre-revenue with no disclosed pricing or commercial products. The business model anticipates revenue through licensing/royalty arrangements, partnership deals, or direct pharmaceutical sales following regulatory approval. The company is venture-backed, having raised approximately $38.4M in equity ($7M seed, $31.4M Series A, $23.3M Series B) plus a $22.5M non-dilutive contract from the Defense Threat Reduction Agency (DTRA) for Lassa Fever development. Backers include CAM Capital, Polaris Partners, Bioqube Ventures, Oberland Capital, and Samsara Biocapital. Operational footprint spans Carlsbad, CA (headquarters), San Diego (JLABS), Belgium (European subsidiary), and Australia (clinical operations).

Short descriptiontext

Primmune Therapeutics is a clinical-stage biotechnology company developing PRTX007, an orally administered TLR7 agonist immunotherapy that activates plasmacytoid dendritic cells to generate interferon-driven innate immune responses for oncology and viral disease indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology therapeutics, TLR7 agonist immunotherapy, small-molecule cancer drugs, antiviral immunotherapy, clinical-stage biotechnology
Industry2 codes
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Immuno-oncology biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeLicensing Royalties
Description

Primmune is a clinical-stage biotech with no current revenue. The company is developing PRTX007 through clinical trials for cancer and viral disease indications. Revenue will be generated upon regulatory approval and commercialization, either through direct sales, partnerships, or licensing agreements.

primmunerx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1TherAjuvant
Description

A proprietary term coined by Primmune Therapeutics to reference its lead candidate PRTX007, describing its combination of therapeutic and adjuvant mechanisms of action. PRTX007 is designed to provide immediate benefit through controlled stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses.

primmunerx.com
Core offering1 text field

Primmune Therapeutics is developing PRTX007, an orally administered, systemically active small-molecule toll-like receptor 7 (TLR7) agonist designed to activate plasmacytoid dendritic cells (pDCs) and selectively trigger interferon-associated innate immune programs. The company is advancing PRTX007 through Phase 1 and Phase 2 clinical trials for oncology indications (including combination with anti-PD-1 therapy in Stage III resectable melanoma), viral diseases (Lassa fever, RSV, COVID-19, hepatitis B and D), and pre-cancerous HPV-driven lesions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 119 healthy volunteers treated with PRTX007 across two Phase 1 studies demonstrating favorable safety profile with no serious adverse events observed
Product overview1 text field

Primmune Therapeutics is a clinical-stage biotechnology company developing a single lead product candidate, PRTX007, as a novel orally-administered TLR7 agonist immunotherapy. The company was founded to develop systemic cancer immunotherapies that activate both innate and adaptive immunity through targeted activation of plasmacytoid dendritic cells. PRTX007 represents the company's entire clinical portfolio and is being advanced for oncology applications (solid tumors, melanoma in combination with anti-PD-1 therapy) and antiviral applications (Lassa fever via DTRA contract). The company uses the term TherAjuvants™ to describe its approach combining therapeutic and adjuvant mechanisms in a single molecule.

Product and service1 record
1PRTX007
CategoryImmuno-oncology small-molecule drug candidate
Description

PRTX007 is a novel, orally administered, systemically active small-molecule toll-like receptor 7 (TLR7) agonist immunotherapy designed in-house to activate plasmacytoid dendritic cells (pDCs) and selectively drive interferon-associated innate immune programs while minimizing NF-κB-driven pro-inflammatory pathways. It is being developed for solid tumors (including Stage III resectable melanoma in combination with anti-PD-1 therapy), viral diseases (Lassa fever under a DTRA contract, RSV, COVID-19, hepatitis B and D), and HPV-driven high-grade squamous intra-epithelial lesions (HSIL). PRTX007 has been administered to 119 healthy volunteers across two Phase 1 studies demonstrating favorable safety and consistent systemic immune engagement without serious adverse events.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-01-26
Description

Novotech serves as the clinical research organization (CRO) for Study PRTX007-003, a Phase 2 neoadjuvant efficacy study in Stage III resectable melanoma being conducted entirely in Australia.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Nektar developed NKTR-262, a TLR7/8 agonist conjugated polymer for combination cancer immunotherapy. Directly comparable mechanism (systemic TLR7/8 agonism) and oncology indication focus, though at a later clinical stage.

TypeDirect peer
Description

Bolt is developing TLR7/8 agonist-based immune-stimulating antibody conjugates (ISACs) for cancer. Similar innate immune activation mechanism via TLR engagement and oncology focus makes it a direct clinical-stage competitor in the TLR agonist immunotherapy space.

TypeDirect peer
Description

Ventyx has developed TLR7/8 agonists as part of its immunology pipeline. Direct comparable in TLR-targeted small-molecule drug development for immune-mediated diseases, though with somewhat different therapeutic positioning.

TypeBroad incumbent
Description

Dynavax commercializes HEPLISAV-B, a TLR9 agonist vaccine adjuvant for hepatitis B. Comparable TLR-targeted immunotherapy platform with approved product, but focuses on vaccine adjuvants rather than direct anti-tumor immune activation.

TypeEmerging player
Description

Primmune co-founders James Appleman and Stephen Webber previously co-founded eFFECTOR, which develops translation-regulating cancer immunotherapies. Overlapping scientific DNA and shared investor relationships make it thematically comparable in cancer immunotherapy drug development.

TypeEmerging player
Description

Asher develops cis-targeting immunotherapies designed to selectively activate immune responses, including TLR-pathway approaches. Comparable in being an early-stage company pursuing engineered immune activation with reduced off-target inflammation.

TypeBroad incumbent
Description

Regeneron acquired Checkmate Pharmaceuticals, which developed CMP-CPS-001 (a TLR9 agonist for cancer). Comparable TLR-agonist cancer immunotherapy approach; Regeneron represents the broad incumbent acquirer in this category.

TypeEmerging player
Description

Sotio develops immunotherapies including immune agonists for solid tumors. Comparable in pursuing innate immune activation strategies for cancer with clinical-stage programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Primmune Therapeutics

Immuno-oncology biopharmaceuticalsprimmunerx.com

Primmune Therapeutics is a clinical-stage biotechnology company developing PRTX007, an orally administered TLR7 agonist immunotherapy that activates plasmacytoid dendritic cells to generate interferon-driven innate immune responses for oncology and viral disease indications.

What Primmune Therapeutics does

Primmune Therapeutics is a clinical-stage biotechnology company developing PRTX007, a novel, orally administered, systemically active small-molecule agonist of toll-like receptor 7 (TLR7). PRTX007 is designed as a prodrug that converts to active metabolite PRX034 and selectively activates plasmacytoid dendritic cells (pDCs) to generate Type I and Type III interferon-associated innate immune programs while deliberately minimizing engagement of NF-κB-driven pro-inflammatory pathways that have historically limited systemic TLR7/8 agonists. The company has coined the term "TherAjuvant" to describe PRTX007's combined therapeutic and adjuvant mechanism, intended to coordinate innate and adaptive immunity while preserving lymph node function.

The company's clinical strategy spans oncology (solid tumors, neoadjuvant melanoma in combination with anti-PD-1 therapy) and viral diseases (RSV, COVID-19, HPV-driven high-grade squamous intraepithelial lesions, Lassa Fever, and hepatitis B/D). As of early 2026, PRTX007 had been administered to 119 healthy volunteers across two Phase 1 studies (PRTX007-001 and PRTX007-002) with a favorable safety profile and no serious adverse events, and the company had initiated a Phase 2 neoadjuvant study in Stage III resectable melanoma in Australia under Novotech. The company is led by co-founders Charlie McDermott (President & CEO), James Appleman (SVP R&D/CSO), Paulo Rangel (CBO), and Stephen Webber (VP Medicinal Chemistry), with a recent CMO appointment of Andrew Sharabi, MD, PhD.

Primmune is pre-revenue with no disclosed pricing or commercial products. The business model anticipates revenue through licensing/royalty arrangements, partnership deals, or direct pharmaceutical sales following regulatory approval. The company is venture-backed, having raised approximately $38.4M in equity ($7M seed, $31.4M Series A, $23.3M Series B) plus a $22.5M non-dilutive contract from the Defense Threat Reduction Agency (DTRA) for Lassa Fever development. Backers include CAM Capital, Polaris Partners, Bioqube Ventures, Oberland Capital, and Samsara Biocapital. Operational footprint spans Carlsbad, CA (headquarters), San Diego (JLABS), Belgium (European subsidiary), and Australia (clinical operations).

Primmune Therapeutics firmographics

Firmographics
Name
Primmune Therapeutics
Legal name
Primmune Therapeutics, Inc.
Website
https://primmunerx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Primmune Therapeutics is a clinical-stage biotechnology company developing PRTX007, an orally administered TLR7 agonist immunotherapy that activates plasmacytoid dendritic cells to generate interferon-driven innate immune responses for oncology and viral disease indications.
Ownership category
akta.pro rank

Primmune Therapeutics industry classification

Industry
Product category
Immuno-oncology biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Immuno-oncology therapeutics
  • TLR7 agonist immunotherapy
  • Small-molecule cancer drugs
  • Antiviral immunotherapy
  • Clinical-stage biotechnology

Where Primmune Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Primmune Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Primmune is a clinical-stage biotech with no current revenue. The company is developing PRTX007 through clinical trials for cancer and viral disease indications. Revenue will be generated upon regulatory approval and commercialization, either through direct sales, partnerships, or licensing agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Primmune Therapeutics product offering

Product offering

Core offering

Primmune Therapeutics is developing PRTX007, an orally administered, systemically active small-molecule toll-like receptor 7 (TLR7) agonist designed to activate plasmacytoid dendritic cells (pDCs) and selectively trigger interferon-associated innate immune programs. The company is advancing PRTX007 through Phase 1 and Phase 2 clinical trials for oncology indications (including combination with anti-PD-1 therapy in Stage III resectable melanoma), viral diseases (Lassa fever, RSV, COVID-19, hepatitis B and D), and pre-cancerous HPV-driven lesions.

Product overview

Primmune Therapeutics is a clinical-stage biotechnology company developing a single lead product candidate, PRTX007, as a novel orally-administered TLR7 agonist immunotherapy. The company was founded to develop systemic cancer immunotherapies that activate both innate and adaptive immunity through targeted activation of plasmacytoid dendritic cells. PRTX007 represents the company's entire clinical portfolio and is being advanced for oncology applications (solid tumors, melanoma in combination with anti-PD-1 therapy) and antiviral applications (Lassa fever via DTRA contract). The company uses the term TherAjuvants™ to describe its approach combining therapeutic and adjuvant mechanisms in a single molecule.

Differentiator

Problem solved

Functional benefit

Brands

  • TherAjuvant: A proprietary term coined by Primmune Therapeutics to reference its lead candidate PRTX007, describing its combination of therapeutic and adjuvant mechanisms of action. PRTX007 is designed to provide immediate benefit through controlled stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses.

Products and services

  • PRTX007 PRTX007 is a novel, orally administered, systemically active small-molecule toll-like receptor 7 (TLR7) agonist immunotherapy designed in-house to activate plasmacytoid dendritic cells (pDCs) and selectively drive interferon-associated innate immune programs while minimizing NF-κB-driven pro-inflammatory pathways. It is being developed for solid tumors (including Stage III resectable melanoma in combination with anti-PD-1 therapy), viral diseases (Lassa fever under a DTRA contract, RSV, COVID-19, hepatitis B and D), and HPV-driven high-grade squamous intra-epithelial lesions (HSIL). PRTX007 has been administered to 119 healthy volunteers across two Phase 1 studies demonstrating favorable safety and consistent systemic immune engagement without serious adverse events.

Quantifiable outcome

  • 119 healthy volunteers treated with PRTX007 across two Phase 1 studies demonstrating favorable safety profile with no serious adverse events observed

Companies that use Primmune Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Primmune Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Primmune Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NovotechmajorImplementation/ SI/ Consulting Partner · 26 January 2026Novotech serves as the clinical research organization (CRO) for Study PRTX007-003, a Phase 2 neoadjuvant efficacy study in Stage III resectable melanoma being conducted entirely in Australia.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Primmune Therapeutics competitors and assessment

Company assessment

Direct peers

  • Nektar Therapeutics: Nektar developed NKTR-262, a TLR7/8 agonist conjugated polymer for combination cancer immunotherapy. Directly comparable mechanism (systemic TLR7/8 agonism) and oncology indication focus, though at a later clinical stage.
  • Bolt Biotherapeutics: Bolt is developing TLR7/8 agonist-based immune-stimulating antibody conjugates (ISACs) for cancer. Similar innate immune activation mechanism via TLR engagement and oncology focus makes it a direct clinical-stage competitor in the TLR agonist immunotherapy space.
  • Ventyx Biosciences: Ventyx has developed TLR7/8 agonists as part of its immunology pipeline. Direct comparable in TLR-targeted small-molecule drug development for immune-mediated diseases, though with somewhat different therapeutic positioning.

Broad incumbents

  • Dynavax Technologies: Dynavax commercializes HEPLISAV-B, a TLR9 agonist vaccine adjuvant for hepatitis B. Comparable TLR-targeted immunotherapy platform with approved product, but focuses on vaccine adjuvants rather than direct anti-tumor immune activation.
  • Regeneron (Checkmate Pharmaceuticals): Regeneron acquired Checkmate Pharmaceuticals, which developed CMP-CPS-001 (a TLR9 agonist for cancer). Comparable TLR-agonist cancer immunotherapy approach; Regeneron represents the broad incumbent acquirer in this category.

Emerging players

  • eFFECTOR Therapeutics: Primmune co-founders James Appleman and Stephen Webber previously co-founded eFFECTOR, which develops translation-regulating cancer immunotherapies. Overlapping scientific DNA and shared investor relationships make it thematically comparable in cancer immunotherapy drug development.
  • Asher Biotherapeutics: Asher develops cis-targeting immunotherapies designed to selectively activate immune responses, including TLR-pathway approaches. Comparable in being an early-stage company pursuing engineered immune activation with reduced off-target inflammation.
  • Sotio Biotech: Sotio develops immunotherapies including immune agonists for solid tumors. Comparable in pursuing innate immune activation strategies for cancer with clinical-stage programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Primmune Therapeutics social profiles

Digital presence

Primmune Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Primmune Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Primmune Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Primmune Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Primmune Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Primmune Therapeutics

What does Primmune Therapeutics do?

Primmune Therapeutics is developing PRTX007, an orally administered, systemically active small-molecule toll-like receptor 7 (TLR7) agonist designed to activate plasmacytoid dendritic cells (pDCs) and selectively trigger interferon-associated innate immune programs. The company is advancing PRTX007 through Phase 1 and Phase 2 clinical trials for oncology indications (including combination with anti-PD-1 therapy in Stage III resectable melanoma), viral diseases (Lassa fever, RSV, COVID-19, hepatitis B and D), and pre-cancerous HPV-driven lesions.

Is Primmune Therapeutics a public or private company?

Primmune Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Primmune Therapeutics founded?

Primmune Therapeutics was founded in 2019. It employs 1 to 10 people.

Where is Primmune Therapeutics based?

Primmune Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Primmune Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are Primmune Therapeutics's main competitors?

Direct peers on record are Nektar Therapeutics, Bolt Biotherapeutics and Ventyx Biosciences. Broad incumbents are Dynavax Technologies and Regeneron (Checkmate Pharmaceuticals). Emerging players are eFFECTOR Therapeutics, Asher Biotherapeutics and Sotio Biotech.

Does Primmune Therapeutics have an API?

No public API is recorded for Primmune Therapeutics.

What industry is Primmune Therapeutics in?

Primmune Therapeutics's product category is Immuno-oncology biopharmaceuticals. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies, with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Los Angeles TimesAdvancing Solid Tumor Immunotherapy: Primmune Therapeutics Raises $8.6MPrimmune Therapeutics announced the close of an additional $8.6 million tranche in its Series B financing, bringing the total raised to $23.3 million with support from investors Bioqube Ventures, Oberland Capital, and Samsara Biocapital. The company plans to use these funds to launch a Phase 2 study for its oral immunotherapy PRTX007 in patients with Stage III melanoma, which will be conducted in Australia by Primmune Therapeutics Pty Ltd. alongside contract research organization Novotech.Pulse 2.0Primmune Therapeutics: $8.6 Million Raised For Cclinical Development Of PRTX007Primmune Therapeutics raised $8.6 million in a Series B financing round, bringing total funding to $23.3 million. The capital will support clinical development of PRTX007, an orally administered TLR7 agonist for solid tumors. The company plans to initiate a Phase 2 neoadjuvant study in Australia.FinSMEsPrimmune Therapeutics Raises $8.6M in Additional Series B FundingPrimmune Therapeutics raised $8.6M in additional Series B funding from Bioqube Ventures, Oberland Capital, and Samsara Biocapital, bringing its total Series B to $23.3M. The Carlsbad, California-based clinical-stage therapeutics company will use the proceeds to initiate Study PRTX007-003, a Phase 2 neoadjuvant efficacy study evaluating PRTX007 in combination with standard-of-care anti-PD-1 therapy in patients with Stage III resectable melanoma.BioSpacePrimmune Therapeutics Announces Additional Close of Series B FinancingPrimmune Therapeutics announced an additional close of its Series B financing round totaling $8.6 million, bringing the total Series B raise to $23.3 million, with participation from Bioqube Ventures, Oberland Capital, and Samsara Biocapital. The funds will support the clinical development of PRTX007, a novel toll-like receptor 7 (TLR7) agonist immunotherapy for solid tumors, including the initiation of a Phase 2 neoadjuvant efficacy study in combination with anti-PD-1 therapy for Stage III resectable melanoma. The study will be conducted entirely in Australia with Novotech serving as the clinical research organization.GlobeNewswirePrimmune Therapeutics Announces Additional Close of Series B FinancingPrimmune Therapeutics closed an additional $8.6 million in its Series B financing, bringing the total to $23.3 million. The funds will support clinical development of PRTX007, a TLR7 agonist, and initiate a Phase 2 neoadjuvant study in Stage III melanoma. The study will be conducted in Australia with Novotech as CRO.GlobeNewswirePrimmune Therapeutics Announces Additional Close of Series B FinancingPrimmune Therapeutics announced an additional close of its Series B financing round, raising an additional $8.6 million that brings the total Series B to $23.3 million, with participation from Bioqube Ventures, Oberland Capital, and Samsara Biocapital. The funds will support clinical development of PRTX007, a novel orally administered TLR7 agonist immunotherapy for solid tumors. The company will initiate Study PRTX007-003, a Phase 2 neoadjuvant efficacy study in Stage III resectable melanoma patients, to be conducted entirely in Australia with Novotech serving as the clinical research organization.Venture Capital Access OnlinePrimmune Therapeutics Announces Additional Close of Series B FinancingPrimmune Therapeutics announced an additional close of its Series B financing round bringing the total raised to $23.3 million, with participation from Bioqube Ventures, Oberland Capital, and Samsara Biocapital. The funds will support clinical development of PRTX007, a novel orally administered TLR7 agonist immunotherapy for solid tumors, including a Phase 2 neoadjuvant study in resectable melanoma patients. The study will be conducted entirely in Australia in conjunction with Novotech as the clinical research organization.The Manila TimesPrimmune Therapeutics Announces Additional Close of Series B FinancingPrimmune Therapeutics announced an additional close of its Series B financing round, bringing the total raise to $23.3 million, with participation from Bioqube Ventures, Oberland Capital, and Samsara Biocapital. The funds will support clinical development of PRTX007, a novel orally administered TLR7 agonist immunotherapy, including a Phase 2 neoadjuvant study in combination with anti-PD-1 therapy for Stage III resectable melanoma to be conducted in Australia. The company expects this financing to advance PRTX007 into a proof-of-concept study with validated efficacy and safety endpoints.BioSpacePrimmune Therapeutics Receives $8.4 Million in Second Tranche of Series A FinancingPrimmune Therapeutics announced the receipt of an $8.4 million second tranche from its Series A financing, bringing the total equity raised to $31.4 million. These funds will support the clinical development of PRTX007 for acute viral diseases and cancer, following the achievement of initial Phase 1 study milestones. The company plans to expand into efficacy studies for RSV, SARS-CoV-2, HPV-related lesions, and advanced cancer in 2022.San Diego Business JournalPrimmune Therapeutics Aims to Treat Cancers, Viral DiseasesSan Diego-based biotech startup Primmune Therapeutics has closed a $27.4 million Series A financing round led by new investors including Polaris Partners, CAM Capital, Oberland Capital, and Samsara. The company plans to initiate clinical trials for its lead candidate PRTX007 in the middle of next year to evaluate its potential in treating cancers and acute viral diseases.